564PTRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO. (23rd October 2018) - Ettrich, T J; Berger, A W; Decker, T; Hofheinz, R D; Heinemann, V; Hoffmann, T; Hebart, H F; Herrmann, T; Hannig, C-V; Büchner-Steudel, P; Bartholomäus, H; Güthle, M; et al.